DUSHARME MOORE: Open Payments
NPI 1386367092 · JACKSON, MS. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$271 in 16 payments from 7 companies in 2025. Trend: 2023 $178 · 2024 $265 · 2025 $271
Food & beverage: $271
| Company | Payments | Amount |
|---|---|---|
| Novo Nordisk Inc | 5 | $84 |
| Sumitomo Pharma America, Inc. | 5 | $80 |
| ABBVIE INC. | 2 | $33 |
| CVRx, Inc. | 1 | $24 |
| Bayer Healthcare Pharmaceuticals Inc. | 1 | $19 |
| Lilly USA, LLC | 1 | $16 |
| GlaxoSmithKline, LLC. | 1 | $15 |
Products named: GEMTESA, Ozempic, Rybelsus, Barostim Neo System, Kerendia, QULIPTA, MOUNJARO, VRAYLAR.
Industry payments across MS — which companies pay providers there.
